Novartis to acquire Cadent Therapeutics for $770 mn
Novartis gains full rights to Cadent’s NMDAr allosteric modulator program, pre-clinical programs and clinical stage movement…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.